



## PRESS RELEASE

### PIERREL RECEIVES MARKETING AUTHORIZATION FOR ORABLOC® IN LEBANON AND KAZAKHSTAN

**Capua (CE), 2 December 2019 – Pierrel S.p.A.** (Ticker: PRL), global provider of services for the pharmaceutical industry listed on the MTA segment of Borsa Italiana, announces that its subsidiary Pierrel Pharma S.r.l. ("**Pierrel Pharma**") **has obtained the marketing authorization in Lebanon and Kazakhstan for Pierrel articaine dental anesthetic, Orabloc®.**

«The registration of our product Orabloc® in Lebanon and Kazakhstan - says *Fabio Velotti, sole director of Pierrel Pharma* - represents, on a territorial basis and in particular in the Eurasian continent and in the Middle East, a crucial step for our commercial and knowledge network of the product in areas that represent, for different reasons, bridges connecting Europe and Asia».

For Pierrel, Kazakhstan and Lebanon added to Russia, Armenia, Iran, Azerbaijan and Georgia with regard to the Eurasian area, and to Jordan for the Middle East.

It should be noted that the Group has a consolidated commercial position in the USA and Canada, Italy and seven other European countries, as well as in Sudan, Taiwan and Indonesia in the Far East.

The Company currently has 31 ongoing new registrations of the Orabloc® anesthetic in many countries, sells over 32 reference products in 17 different countries and is about to add a further 28 references in the new countries where authorization procedures are underway.

\* \* \*

**Pierrel S.p.A.** specialises in the pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division). Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years' experience in the pharmaceutical sector, being one of Europe's leading producers of local and dental anaesthetics. Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy. [www.pierrelgroup.com](http://www.pierrelgroup.com)



**For further information:**

**Pierrel S.p.A.**

*Investor Relations*

Mr Fulvio Citaredo

E-mail: [investor.relations@pierrelgroup.com](mailto:investor.relations@pierrelgroup.com)

tel. +39 0823 626 111

fax +39 0823 626 228

**Spriano Communication & Partners S.r.l.**

*Media Relations*

Cristina Tronconi

E-mail: [ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

tel. + 39 3460477901

Jacopo Ghirardi

E-mail: [ufficiostampa@sprianocommunication.com](mailto:ufficiostampa@sprianocommunication.com)

tel. +39 3337139257